Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 465

1.

Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma.

Meyer HA, Tölle A, Jung M, Fritzsche FR, Haendler B, Kristiansen I, Gaspert A, Johannsen M, Jung K, Kristiansen G.

Eur Urol. 2009 Mar;55(3):669-78. doi: 10.1016/j.eururo.2008.04.001. Epub 2008 Apr 9.

PMID:
18450365
2.

Expression of aquaporin 1 in primary renal tumors: a prognostic indicator for clear-cell renal cell carcinoma.

Huang Y, Murakami T, Sano F, Kondo K, Nakaigawa N, Kishida T, Kubota Y, Nagashima Y, Yao M.

Eur Urol. 2009 Oct;56(4):690-8. doi: 10.1016/j.eururo.2008.10.014. Epub 2008 Oct 14.

PMID:
18930582
3.

Editorial comment on: Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma.

Staehler M.

Eur Urol. 2009 Mar;55(3):678. doi: 10.1016/j.eururo.2008.04.002. Epub 2008 Apr 9. No abstract available.

PMID:
18450364
4.

Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.

Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

Clin Cancer Res. 2007 Dec 15;13(24):7388-93.

5.

Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value.

Kempkensteffen C, Hinz S, Christoph F, Krause H, Magheli A, Schrader M, Schostak M, Miller K, Weikert S.

J Cancer Res Clin Oncol. 2008 May;134(5):543-50. Epub 2007 Oct 9.

PMID:
17922292
6.

Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?

Tölle A, Jung M, Lein M, Johannsen M, Miller K, Moch H, Jung K, Kristiansen G.

BMC Cancer. 2009 Jul 21;9:248. doi: 10.1186/1471-2407-9-248.

7.

Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma.

Parker A, Cheville JC, Lohse C, Cerhan JR, Blute ML.

J Urol. 2003 Aug;170(2 Pt 1):420-4.

PMID:
12853790
8.

Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma.

Awakura Y, Nakamura E, Takahashi T, Kotani H, Mikami Y, Kadowaki T, Myoumoto A, Akiyama H, Ito N, Kamoto T, Manabe T, Nobumasa H, Tsujimoto G, Ogawa O.

J Cancer Res Clin Oncol. 2008 Dec;134(12):1363-9. doi: 10.1007/s00432-008-0412-4. Epub 2008 May 16.

PMID:
18483744
9.
10.

Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.

Beck SD, Patel MI, Snyder ME, Kattan MW, Motzer RJ, Reuter VE, Russo P.

Ann Surg Oncol. 2004 Jan;11(1):71-7.

PMID:
14699037
11.

Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins.

Esseghir S, Kennedy A, Seedhar P, Nerurkar A, Poulsom R, Reis-Filho JS, Isacke CM.

Clin Cancer Res. 2007 Jun 1;13(11):3164-73.

12.

The diagnostic and prognostic utility of claudin expression in renal cell neoplasms.

Lechpammer M, Resnick MB, Sabo E, Yakirevich E, Greaves WO, Sciandra KT, Tavares R, Noble LC, DeLellis RA, Wang LJ.

Mod Pathol. 2008 Nov;21(11):1320-9. doi: 10.1038/modpathol.2008.116. Epub 2008 Jun 27. Erratum in: Mod Pathol. 2009 Feb;22(2):321.

13.

Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas.

Fritzsche FR, Oelrich B, Johannsen M, Kristiansen I, Moch H, Jung K, Kristiansen G.

Clin Cancer Res. 2008 Nov 1;14(21):7035-42. doi: 10.1158/1078-0432.CCR-08-0855.

14.

p53 expression in correlation to clinical outcome in patients with renal cell carcinoma.

Ljungberg B, Bozoky B, Kovacs G, Stattin P, Farrelly E, Nylander K, Landberg G.

Scand J Urol Nephrol. 2001 Feb;35(1):15-20.

PMID:
11291681
15.

Mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: a tissue microarray and quantitative RT-PCR study.

Yakirevich E, Morris DJ, Tavares R, Meitner PA, Lechpammer M, Noble L, de Rodriguez AF, Gomez-Sanchez CE, Wang LJ, Sabo E, Delellis RA, Resnick MB.

Am J Surg Pathol. 2008 Jun;32(6):874-83. doi: 10.1097/PAS.0b013e31815f2362.

PMID:
18408592
16.
17.

Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma.

Ronkainen H, Hirvikoski P, Kauppila S, Vaarala MH.

Oncol Rep. 2011 Jan;25(1):129-33.

PMID:
21109967
18.

BIGH3 is overexpressed in clear cell renal cell carcinoma.

Yamanaka M, Kimura F, Kagata Y, Kondoh N, Asano T, Yamamoto M, Hayakawa M.

Oncol Rep. 2008 Apr;19(4):865-74.

PMID:
18357369
19.

The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis.

Elsamman EM, Fukumori T, Tanimoto S, Nakanishi R, Takahashi M, Toida K, Kanayama HO.

BJU Int. 2006 Sep;98(3):668-73.

20.

Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.

Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, Zincke H, Blute ML, Cheville JC, Kwon ED.

Cancer. 2005 Aug 1;104(3):511-20.

Supplemental Content

Support Center